{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:42:20Z","timestamp":1762299740933,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.vaccine.2021.03.024","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T21:17:45Z","timestamp":1616188665000},"page":"2475-2478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A half-century of meningococcal vaccines"],"prefix":"10.1016","volume":"39","author":[{"given":"Andrew W.","family":"Artenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.03.024_b0005","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcemia, and Neisseria meningitidis","volume":"368","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.03.024_b0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0035-9203(99)90106-2","article-title":"Meningococcal meningitis in Africa","volume":"93","author":"Greenwood","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.03.024_b0015","article-title":"Global epidemiology of invasive meningococcal disease","volume":"10","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2021.03.024_b0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/00034983.1997.11813203","article-title":"Meningococcal disease in Africa","volume":"91","author":"Hart","year":"1997","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.vaccine.2021.03.024_b0025","unstructured":"Brundage JF, Zollinger WD. Evolution of meningococcal disease epidemiology in the U.S. Army. In: Vedros NA, editor. Evolution of meningococcal disease, vol. 1. CRC Press: Boca Raton; 1987."},{"key":"10.1016\/j.vaccine.2021.03.024_b0030","first-page":"171","article-title":"Meningococcal infections: fort Ord and California","volume":"102","author":"Brown","year":"1965","journal-title":"Calif Med"},{"year":"2013","series-title":"In the blink of an eye: the deadly story of epidemic meningitis","author":"Artenstein","key":"10.1016\/j.vaccine.2021.03.024_b0035"},{"key":"10.1016\/j.vaccine.2021.03.024_b0040","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1097\/CCM.0b013e31829eb98f","article-title":"Sepsis and scientific revolutions","volume":"41","author":"Artenstein","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1084\/jem.26.4.477","article-title":"The elaboration of specific soluble substance by pneumococcus during growth","volume":"26","author":"Dochez","year":"1917","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.38.1.73","article-title":"The soluble specific substance of pneumococcus","volume":"38","author":"Heidelberger","year":"1923","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1084\/jem.52.4.573","article-title":"Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide","volume":"52","author":"Francis","year":"1930","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.54.5.637","article-title":"Specific cutaneous reactions and circulating antibodies in the course of lobar pneumonia. I. Cases receiving no serum therapy","volume":"54","author":"Finland","year":"1931","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.55.6.853","article-title":"Specific antibody response of human subjects to intracutaneous injection of pneumococcus products","volume":"55","author":"Finland","year":"1932","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.29.4.285","article-title":"Cutaneous reactions and antibody response to intracutaneous injection of pneumococcus polysaccharides","volume":"29","author":"Finland","year":"1935","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.03.024_b0075","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2307\/4582686","article-title":"Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylactic value of a pneumococcus antigen","volume":"53","author":"Ekwurzel","year":"1938","journal-title":"Public Health Rep"},{"key":"10.1016\/j.vaccine.2021.03.024_b0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.82.6.445","article-title":"Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides","volume":"82","author":"MacLeod","year":"1945","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.bi.48.070179.000245","article-title":"A \u201cpure\u201d organic chemist\u2019s downward path: chapter 2\u2014the years at P and S","volume":"48","author":"Heidelberger","year":"1979","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.vaccine.2021.03.024_b0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0095","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0100","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","article-title":"Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0110","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1084\/jem.129.6.1385","article-title":"Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0120","first-page":"279","article-title":"Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969\u20131970","volume":"45","author":"Gold","year":"1971","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2021.03.024_b0125","first-page":"197","article-title":"Control of meningococcal meningitis with meningococcal vaccines","volume":"48","author":"Artenstein","year":"1975","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0130","first-page":"301","article-title":"A serogroup A meningococcal polysaccharide vaccine: studies in the Sudan to combat cerebrospinal meningitis caused by Neisseria meningitidis group A","volume":"49","author":"Erwa","year":"1973","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2021.03.024_b0135","first-page":"667","article-title":"A controlled field trial of a serogroup A meningococcal polysaccharide vaccine","volume":"48","author":"Wahdan","year":"1973","journal-title":"Bull WHO"},{"key":"10.1016\/j.vaccine.2021.03.024_b0140","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(75)92125-X","article-title":"Effect of group-A meningococcal vaccine in Army recruits in Finland","volume":"2","author":"M\u00e4kel\u00e4","year":"1975","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2021.03.024_b0145","first-page":"184","article-title":"Prevention of pneumococcal pneumonia by vaccination","volume":"89","author":"Austrian","year":"1976","journal-title":"Trans Assoc Am Phys"},{"key":"10.1016\/j.vaccine.2021.03.024_b0150","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM198406143102404","article-title":"Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine","volume":"310","author":"Peltola","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0155","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/infdis\/129.5.568","article-title":"Epidemic disease due to serogroup C Neisseria meningitidis in S\u00e3o Paulo","volume":"129","author":"Morais","year":"1974","journal-title":"Brazil. J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.024_b0160","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0165","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM199011153232004","article-title":"A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Hemophilus influenzae type b disease","volume":"323","author":"Eskola","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.03.024_b0170","doi-asserted-by":"crossref","first-page":"19506","DOI":"10.1016\/S0140-6736(00)03594-7","article-title":"Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England","volume":"357","author":"Ramsay","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2021.03.024_b0175","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/microorganisms8101521","article-title":"Vaccines against meningococcal diseases","volume":"8","author":"Pizza","year":"2020","journal-title":"Microorg"},{"key":"10.1016\/j.vaccine.2021.03.024_b0180","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","article-title":"Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u20132015: an analysis of surveillance data","volume":"17","author":"Trotter","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.024_b0185","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/microorganisms8111675","article-title":"Herd protection against meningococcal disease through vaccination","volume":"8","author":"Clark","year":"2020","journal-title":"Microorg"},{"key":"10.1016\/j.vaccine.2021.03.024_b0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:45Z","timestamp":1759402605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":38,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0264410X21002929"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A half-century of meningococcal vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}